MultiCell Technologies' Common Stock To Trade Under New Ticker Symbol Today
Friday May 20, 8:40 am ET
LINCOLN, R.I.--(BUSINESS WIRE)--May 20, 2005--MultiCell Technologies, Inc. (OTCBB: MCET - News), a leading supplier of immortalized non-tumorigenic human hepatocytes as pharmaceutical candidate optimization tools, announced that beginning today, its common stock will begin trading on the Over-The-Counter Bulletin Board under the ticker symbol MCET. Previously, the Company's common stock traded under the ticker symbol MUCL.
MultiCell Technologies develops liver cell-based products for commercial and therapeutic applications. MultiCell's non-tumorigenic functional immortalized human liver cells offer pharmaceutical companies an effective alternative to primary animal cells for drug discovery screening. MultiCell's patented strategies for isolation of adult human liver stem cells avoid the ethical and contamination issues associated with embryonic stem cells.
MultiCell's new headquarters and laboratories are at 701 George Washington Highway, Lincoln, Rhode Island 02865. For more information about MultiCell and its Xenogenics subsidiary, call (401) 333-0610 or see www.multicelltech.com.
Except for the historical information contained herein, this press release contains forward-looking statements, including, without limitation, statements containing the words, "believes," "anticipates," "expects," and words of similar import. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those set forth in the forward looking statements. These risks include, among others, the impact of the reverse stock split on the common stock price and the company's ability to attract institutional ownership and analyst coverage, the risk that the company may not achieve profitability, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission including the Company's Annual Report on form 10-KSB for the fiscal year ended November 30, 2004, and its Quarterly Reports on Form 10-QSB and other periodic filings. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
--------------------------------------------------------------------------------
Contact:
MultiCell Technologies
Jerry Newmin, 401-333-0610
or
CEOcast, Inc. for MultiCell
Ed Lewis, 212-732-4300
--------------------------------------------------------------------------------
Source: MultiCell Technologies, Inc.
biz.yahoo.com |
